Aaron J. Kowalski: Impact of Rising Insulin Costs

Dear JDRF Supporter,

On behalf of JDRF, I testified today before the U.S. House of Representatives Committee on Energy & Commerce Oversight & Investigations Subcommittee on the impact of rising insulin costs.

I told Congress that no one should suffer or die because they cannot access insulin. At a time when new innovations can enable people with type 1 diabetes (T1D) to live longer, healthier lives than ever before, the dramatic rise in the cost of insulin is undercutting this progress.

JDRF recognizes that people with T1D are struggling to pay for their insulin, which is why today we called on Congress for systemic change to the healthcare system. That includes manufacturers lowering the list price of insulin; eliminating drug rebates; health insurers and employers providing affordable coverage that reflects insulin’s role as a life-saving drug; doing more to help those without insurance access insulin; and continued investment in research to improve outcomes for people with T1D.

To watch my full testimony, click here.

How you can help

You can help amplify our message to Congress that people with T1D must have access to affordable insulin. We’re asking our community to post on social media about how the price of insulin affects them. Please tag JDRF on TwitterFacebook, or Instagram and use the hashtag #Coverage2Control.

You can also send a comment letter to the U.S. Department of Health and Human Services in support of its proposal to end the use of rebates in Federally funded health insurance plans. The deadline to send a letter is April 8. For more information on how to send a letter, click here.

Thank you for taking action as we continue to fight to make insulin more affordable!

Aaron J. Kowalski, Ph.D.
Chief Mission Officer